Nakamura S, Nakata K, Katae H, Minami A, Kashimoto S, Yamagishi J, Takase Y, Shimizu M
Antimicrob Agents Chemother. 1983 May;23(5):742-9. doi: 10.1128/AAC.23.5.742.
AT-2266 (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine-3-carboxylic acid) showed marked activity in vivo when administered orally to mice bearing systemic, pulmonary, dermal, or urinary tract infections due to variety of organisms. The activity of AT-2266 was uniformly higher than those of norfloxacin, pipemidic acid, and nalidixic acid against all of the infections. The activity of AT-2266 administered orally was almost comparable to that of gentamicin administered subcutaneously against urinary tract infections due to gram-negative organisms but was generally lower against other infections. AT-2266 exhibited significant activity against infections due to gentamicin-resistant and nalidixic acid-resistant organisms.
AT - 2266（1 - 乙基 - 6 - 氟 - 1,4 - 二氢 - 4 - 氧代 - 7 - （1 - 哌嗪基）- 1,8 - 萘啶 - 3 - 羧酸）对因多种微生物引起的全身性、肺部、皮肤或尿路感染的小鼠口服给药时，在体内显示出显著活性。AT - 2266对所有感染的活性均始终高于诺氟沙星、吡哌酸和萘啶酸。口服给药的AT - 2266对革兰氏阴性菌引起的尿路感染的活性几乎与皮下注射庆大霉素的活性相当，但对其他感染的活性通常较低。AT - 2266对庆大霉素耐药和萘啶酸耐药的微生物引起的感染表现出显著活性。
